Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8
S Lacour1, A Hammann, A Wotawa
1Institut National de la Santé et de la Recherche Médicale U517, Facultés de Médicine et de Pharmacie, Dijon, France.
Abstract:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a new cytokine that was proposed to specifically induce apoptosis of cancer cells. In tumor cells that are resistant to the cytokine, subtoxic concentrations of chemotherapeutic drugs can restore the response to TRAIL. The present study further explores the mechanisms that determine tumor cell sensitivity to TRAIL by comparing four human colon carcinoma cell lines We show that colon cancer cell sensitivity to TRAIL-induced apoptosis and cytotoxicity correlates with the expression of the death receptors TRAIL-R1 and TRAIL-R2 at the cell surface, as determined by now cytometry, whereas the two decoy receptors TRAIL-R3 and TRAIL-R4 can be detected only in permeabilized cells. Clinically relevant concentrations of cisplatin and doxorubicin sensitize the most resistant colon cancer cell lines to TRAIL-induced cell death without modifying the expression nor the localization of TRAIL receptors in these cells. TRAIL induces the activation of procaspase-8 and triggers caspase-dependent apoptosis off colon cancer cells. Cytotoxic drugs lower the signaling threshold required for TRAIL-induced procaspase-8 activation. In turn, caspase-8 cleaves Bid, a BH3 domain-containing proapoptotic molecule of the Bcl-2 family and activates effector caspases. Together, these data indicate that chemotherapeutic drugs sensitize colon tumor cells to TRAIL-mediated caspase-8 activation and apoptosis.
Insights
Chemotherapy sensitizes resistant colon cancer cells to TRAIL-induced apoptosis by lowering the signaling threshold for caspase-8 activation. This enhances the effectiveness of TRAIL therapy in colon tumors.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cancer cell apoptosis.
- Cancer cells can develop resistance to TRAIL.
- Chemotherapeutic drugs can restore TRAIL sensitivity in resistant tumor cells.
Purpose of the Study:
- To investigate the mechanisms underlying colon cancer cell sensitivity to TRAIL.
- To explore how chemotherapeutic drugs modulate TRAIL-induced apoptosis in colon cancer.
Main Methods:
- Comparison of four human colon carcinoma cell lines.
- Flow cytometry to assess TRAIL receptor expression.
- Analysis of caspase activation pathways.
- Treatment with TRAIL, cisplatin, and doxorubicin.
Main Results:
- Colon cancer cell sensitivity to TRAIL correlates with TRAIL-R1 and TRAIL-R2 expression.
- Chemotherapeutic drugs (cisplatin, doxorubicin) sensitize resistant cells to TRAIL without altering receptor expression.
- TRAIL induces caspase-dependent apoptosis via procaspase-8 activation.
- Chemotherapy lowers the threshold for TRAIL-induced procaspase-8 activation, leading to Bid cleavage and effector caspase activation.
Conclusions:
- Chemotherapeutic drugs enhance TRAIL-mediated apoptosis in colon cancer by sensitizing the caspase-8 activation pathway.
- This combination strategy offers a potential approach to overcome TRAIL resistance in colon tumors.
Related Concept Videos
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Caspases
Apoptosis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

